Cannaray Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Reverse Merger
  • (Cancelled)

  • Investors
  • 5

Cannaray General Information

Description

Producer of cannabis-based medical products intended to cater to the normal functioning of the immune system. The company provides hemp extract-based products such as oil, gummies, capsules, and creams that are mainly used for the treatment of chemotherapy-induced nausea, vomiting, epilepsy, multiple sclerosis, and chronic pain, enabling patients to get treated with less risk and side effects.

Contact Information

Website
cannaraycbd.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Bow Churchyard
  • London EC4M 9DQ
  • England, United Kingdom
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Consumer Non-Durables
Biotechnology
Vertical(s)
Corporate Office
  • 1 Bow Churchyard
  • London EC4M 9DQ
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cannaray Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Reverse Merger 26-Sep-2022 Cancelled Generating Revenue
3. Early Stage VC 04-Apr-2022 Completed Generating Revenue
2. Early Stage VC 01-Jan-2021 $9.5M Completed Generating Revenue
1. Early Stage VC (Series A) 09-Sep-2019 $9.5M $9.5M Completed Generating Revenue
To view Cannaray’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cannaray Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cannaray Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alpha Blue Ocean Family Office Minority
Channel 4 Ventures Corporate Venture Capital Minority
Three Bridges Private Capital Venture Capital Minority
Enexis (Sweden) Venture Capital Minority
Plutus Investment Group Family Office Minority
To view Cannaray’s complete investors history, request access »

Cannaray Acquisitions (2)

Cannaray’s most recent deal was a Merger/Acquisition with Aqualitas (Consumer Non-Durables) for . The deal was made on 12-Mar-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aqualitas (Consumer Non-Durables) 12-Mar-2024 Merger/Acquisition Specialty Retail
Therismos 31-Jul-2019 Merger/Acquisition Distributors (Healthcare)
To view Cannaray’s complete acquisitions history, request access »

Cannaray Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Therismos Bromsgrove, United Kingdom 2011

Cannaray FAQs

  • When was Cannaray founded?

    Cannaray was founded in 2018.

  • Where is Cannaray headquartered?

    Cannaray is headquartered in London, United Kingdom.

  • What is the size of Cannaray?

    Cannaray has 16 total employees.

  • What industry is Cannaray in?

    Cannaray’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Cannaray a private or public company?

    Cannaray is a Private company.

  • What is Cannaray’s current revenue?

    The current revenue for Cannaray is .

  • How much funding has Cannaray raised over time?

    Cannaray has raised $22.6M.

  • Who are Cannaray’s investors?

    Alpha Blue Ocean, Channel 4 Ventures, Three Bridges Private Capital, Enexis (Sweden), and Plutus Investment Group have invested in Cannaray.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process